Update shared on08 Aug 2025
Fair value Decreased 3.50%The modest reduction in PROCEPT BioRobotics’ consensus price target to $65.75 reflects a slight downward revision in the company’s future P/E multiple, while profitability remains stable.
What's in the News
- Raised full-year 2025 revenue guidance to $325.5 million, representing 45% year-over-year growth; projected net loss for 2025 is $83.5 million.
- Announced CEO transition: Larry L. Wood appointed as Chief Executive Officer effective September 2, 2025, succeeding Dr. Reza Zadno, who will become a consultant to the company.
- Successfully completed three prostate cancer procedures in the WATER IV Prostate Cancer Trial, comparing Aquablation therapy to radical prostatectomy for localized prostate cancer.
Valuation Changes
Summary of Valuation Changes for PROCEPT BioRobotics
- The Consensus Analyst Price Target has fallen slightly from $68.62 to $65.75.
- The Future P/E for PROCEPT BioRobotics has fallen slightly from 81.87x to 77.91x.
- The Net Profit Margin for PROCEPT BioRobotics remained effectively unchanged, moving only marginally from 12.34% to 12.49%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.